Background
==========

Generalized anxiety disorder (GAD) is a chronic condition that is characterized by persistent worry or anxiety that occurs more days than not over a period of at least six months \[[@B1]\]. The condition is frequently difficult to diagnose because of the variety of clinical presentations and the common occurrence of comorbid medical or other psychiatric conditions. Lifetime prevalence has been estimated to be between 4% and 6% \[[@B2]\]; the disease is more common among women than men. GAD is the most common anxiety disorder among patients presenting to primary care physicians \[[@B3],[@B4]\].

Several different types of medications are often used to treat GAD -- specifically, benzodiazepines (e.g., flurazepam, diazepam, chlordiazepoxide), buspirone, tricyclic antidepressants (TCAs) (e.g., amitriptyline, imipramine, doxepin, opipramol), selective serotonin reuptake inhibitors (SSRIs) (e.g., paroxetine. escitalopram), and venlafaxine (a selective serotonin and norepinephrine reuptake inhibitor) \[[@B5]-[@B7]\]. Among these available therapies, benzodiazepines have long been the mainstay of pharmacologic treatment for GAD. While effective, benzodiazepines are associated with excessive sedation and motor impairment \[[@B8]\]; their long-term use is also associated with a risk of physical dependence as well as withdrawal when therapy is discontinued \[[@B6]\]. In one study comparing 4554 persons prescribed benzodiazepines with 13,662 persons receiving other (i.e., non-benzodiazepine) medications who were matched on age, sex, and calendar month in which therapy was initiated, Oster and colleagues found that patients in the former group had a 15% higher risk of an accident-related medical event; those who filled three or more prescriptions for benzodiazepines had a 30% higher risk compared with those who filled only one such prescription \[[@B9]\].

An expert panel convened by Beers in 1991 developed explicit criteria for identifying medication use among nursing home residents that was potentially inappropriate \[[@B10]\]. Recognizing that these criteria were developed specifically for a nursing home population, Beers convened another expert panel in 1997 to develop criteria applicable to the entire population of older persons (≥65 years); the resulting criteria designated some of the drugs used to treat GAD (benzodiazepines, amitriptyline, doxepin) as potentially inappropriate for use in persons aged ≥ 65 years \[[@B11]\]. The panel compiled its list of potentially inappropriate medications without regard to diagnosis or place of residence, and sought to include only those agents whose \". . . potential for adverse outcomes is greater than the potential for benefit\" \[[@B11]\].

While well-known and extensively cited, the Beers\' criteria have been criticized as not providing a sufficient basis for identifying inappropriate prescribing, as they are not indication-specific \[[@B12]\]. A subsequent expert panel convened by Zhan et al. classified 33 medications on the Beers\' list alternatively as always to be avoided, rarely appropriate, and appropriate for some indications \[[@B13]\]. Among drugs that are sometimes used to treat GAD, flurazepam was designated as \"always to be avoided\"; chlordiazepoxide and diazepam were designated as \"rarely appropriate\"; and amitriptyline and doxepin, \"appropriate for some indications\".

In their update of the Beers\' criteria, Fick et al. designated flurazepam, amitriptyline, chlordiazepoxide, doxepin, and anything other than low doses of short-acting benzodiazepines (e.g., \>3 mg lorazepam) as potentially inappropriate for use in older patients; adverse outcomes for all such medications were deemed by the authors to be of high (versus low) severity \[[@B14]\].

Despite their limitations, the 1997 Beers\' criteria have been widely used by researchers to identify potential medication risks \[[@B13],[@B15]-[@B19]\]. An epidemiologic study of noninstitutionalized persons who participated in the 1987 US National Medical Expenditure Survey reported that 23.5% of those aged ≥65 years received at least one of the 20 medications on the Beers\' list \[[@B20]\]. Zhan et al. applied their revised list to persons participating in the 1996 US Medical Expenditure Panel Survey and reported that 21.3% received drugs that were potentially -- albeit not necessarily -- inappropriate, 2.6% received medications that should always be avoided, and 9.1% received drugs that were rarely appropriate; 3.4% of those aged \>65 years had received amitriptyline \[[@B13]\].

Recently, an examination of 2707 older home-care patients from eight countries across Europe found that 19.8% received at least one medication designated as potentially inappropriate; in multivariate analysis, use of anxiolytics was associated with a twofold increase in the likelihood of receiving potentially inappropriate medications \[[@B21]\]. Some of the most commonly used, potentially inappropriate medications in this study were benzodiazepines (diazepam \[3.1% of patients received such therapy\] and chlordiazepoxide \[0.6%\]) and tricyclic antidepressants (amitriptyline \[1.4%\]) -- agents often used for the treatment of GAD.

Although older adults with GAD would appear to often receive potentially inappropriate medications, the actual extent of such use in clinical practice is unknown. Moreover, the generalizability of earlier findings -- based largely on US data -- to other countries is unknown. In this study, we examine the magnitude of exposure of patients aged ≥65 years with GAD to potentially inappropriate medications in Germany, a large European country in which observed patterns of treatment of GAD may possibly be reflective of those throughout Europe.

Methods
=======

Data were obtained from the IMS MediPlus -- Disease Analyzer database; a detailed description of the database and its research capabilities may be found elsewhere \[[@B22]\]. The database is longitudinal in nature, and provides patient-level information on consultations, diagnoses, and treatments from over 900 GP practices throughout Germany, comprising more than 4.2 million patient records and 75 million prescriptions over a 10-year period. The database is compiled by sampling practices throughout Germany, and is designed to be representative of the general population in Germany. All patient identifiers in the database are fully encrypted.

Information in the IMS MediPlus -- Disease Analyzer database includes date of service, diagnoses (in ICD-10 format), actions taken (e.g., referrals to other providers \[i.e., specialists\], dispensing of sick notes \[physician-excused absences from work\]), and medications dispensed, including the dispensing date, the quantity dispensed, the number of days of therapy supplied, and the associated diagnosis (available for about 60% of all prescription records). Selected demographic information is also available, including patient age and gender. All patient-level data can be arrayed chronologically to provide a detailed, longitudinal profile of all medical and pharmacy services rendered by participating GPs. Because this study was retrospective in nature, used completely anonymized data, and did not involve patient contact, institutional review board (IRB) approval was not sought. The database for this study encompassed the period, October 1, 2003 through September 30, 2004 (\"study period\").

The study sample consisted of all patients with any GP office visits or dispensed prescriptions with a diagnosis of GAD (ICD-10 diagnosis code F41.1) during the study period. Persons aged \<65 years as of their first-noted encounter for GAD were excluded from the study sample. All GP encounters were then compiled for all subjects over the one-year period of study.

The prevalence of a number of medically attended comorbidities (i.e., noted by GPs during office or clinic visits) was examined for patients in the study sample, including: (1) neoplasms; (2) anemia and other blood antibody disorders; (3) diabetes; (4) circulatory system disorders; (5) respiratory system disorders; (6) eye, nose, and throat disorders; (7) digestive system disorders; (8) painful neuropathic disorders (e.g., diabetic peripheral neuropathy, post-herpetic neuralgia, causalgia, neuropathic back pain); (9) musculoskeletal system disorders; (10) symptom, signs, ill-defined conditions; (11) somatoform disorders; (12) neurasthenia; (13) substance use disorders; and (14) sleep disorders. Patients were deemed to have these conditions if they had *[any]{.ul}*encounters during the study period with the corresponding diagnosis code(s).

The numbers of patients receiving various medications often used to treat GAD (\"GAD-related medications\") were tabulated. Medications (and corresponding dosages, if relevant \[see below\]) were deemed \"potentially inappropriate\" based on their inclusion in Beers\' 1997 criteria and/or in subsequent updates to these criteria \[[@B11],[@B13],[@B14]\]. Medication regimens designated as potentially inappropriate were as follows: (1) alprazolam (\>2 mg daily); (2) amitriptyline; (3) chlorazepate; (4) chlordiazepoxide; (5) diazepam; (6) doxepin; (7) flurazepam; (8) halazepam; (9) lorazepam (\>3 mg daily); (10) oxazepam (\>60 mg daily); (11) temazepam (\>15 mg daily); (12) triazolam (\>0.25 mg daily); and (13) zolpidem (\>5 mg daily) \[Table [1](#T1){ref-type="table"}\]. Daily dose was calculated using information in the database; in instances where such information was missing, daily dose was assumed equivalent to the modal value from all other prescriptions for the same product with non-missing values.

###### 

Medications for treatment of generalized anxiety disorder

  **Medication Type**                      **Comment**
  ---------------------------------------- ------------------------------------------------------------------
  Benzodiazepines                          
   Short-acting                            
    Alprazolam                             \>2 mg/d deemed potentially inappropriate
    Bromazepam                             
    Lorazepam                              \>3 mg/d deemed potentially inappropriate
    Lormetazepam                           
    Nitrazepam                             
    Oxazepam                               \>60 mg/d deemed potentially inappropriate
    Temazepam                              \>15 mg/d deemed potentially inappropriate
    Tetrazepam                             
    Triazolam                              \>0.25 mg/d deemed potentially inappropriate
    Zolpidem                               \>5 mg/d deemed potentially inappropriate
   Long-acting                             
    Chlordiazepoxide                       All long-acting benzodiazepines deemed potentially inappropriate
    Chlorazepate                           All long-acting benzodiazepines deemed potentially inappropriate
    Clobazam                               All long-acting benzodiazepines deemed potentially inappropriate
    Clonazepam                             All long-acting benzodiazepines deemed potentially inappropriate
    Diazepam                               All long-acting benzodiazepines deemed potentially inappropriate
    Flunitrazepam                          All long-acting benzodiazepines deemed potentially inappropriate
    Flurazepam                             All long-acting benzodiazepines deemed potentially inappropriate
    Halazepam                              All long-acting benzodiazepines deemed potentially inappropriate
    Medazepam                              All long-acting benzodiazepines deemed potentially inappropriate
    Nordazepam                             All long-acting benzodiazepines deemed potentially inappropriate
    Prezepam                               All long-acting benzodiazepines deemed potentially inappropriate
  Tricyclic antidepressants                
   Amitriptyline                           Deemed potentially inappropriate
   Amitriptylinoxide                       
   Clomipramine                            
   Dibenzepin                              
   Desipramine                             
   Doxepin                                 Deemed potentially inappropriate
   Imipramine                              
   Maprotiline                             
   Nortiptyline                            
   Opipramol                               
   Trimipramine                            
  Selective serotonin reuptake inhibitor   
   Escitalopram                            
   Citalopram                              
   Fluoxetine                              
   Fluvoxamine                             
   Paroxetine                              
   Sertraline                              
  Venlafaxine                              
  Hydroxyzine                              Deemed potentially inappropriate
  Buspirone                                
  Pregabalin                               
  Trifluoperazine                          

Medication receipt was ascertained for the overall study sample, as well as within strata defined on the basis of age, sex, and selected comorbidities (e.g., depression, neoplasms, respiratory disorders). The statistical significance of differences within strata was ascertained using chi-square tests and Fisher\'s exact tests, as appropriate. All analyses were conducted using PC-SAS^®^v.9.1 \[[@B23]\].

Results
=======

The study sample consisted of 975 patients, aged ≥65 years, with diagnoses of GAD; mean (± SD) age was 75.0 (± 7.3) years, and 71.6% were women \[Table [2](#T2){ref-type="table"}\]. Twenty-four percent of study subjects had at least one encounter during the study period at which a diagnosis of another anxiety disorder was noted; 29.2% had at least one encounter resulting in a diagnosis of depression. The prevalence of other medically attended comorbidities was high, including circulatory disorders (87.5%), digestive disorders (56.0%), respiratory disorders (42.5%), musculoskeletal disorders (69.5%), painful neuropathies (28.8%), and sleep disorders (24.7%). Ninety-eight percent of patients had at least one comorbidity, and 87.0% had three or more.

###### 

Demographic and clinical characteristics of study subjects (N = 975)\*

  **Characteristic**                          
  ------------------------------------------- ------------
  Age, years                                  
   65--74                                     507 (52.0)
   75--84                                     365 (37.4)
   ≥85                                        103 (10.6)
   Mean (SD)                                  75.0 (7.3)
  Females                                     698 (71.6)
  Males                                       277 (28.4)
  Comorbid conditions                         
   Anxiety disorders                          
    Panic disorder                            17 (1.7)
    OCD                                       2 (0.2)
    PTSD                                      0 (0.0)
    Phobias                                   
     Social phobia                            0 (0.0)
     Agoraphobia                              0 (0.0)
     All other phobias                        10 (1.0)
     Any phobia                               10 (1.0)
    Other anxiety disorders                   215 (22.1)
    Any anxiety disorder (other than GAD)     237 (24.3)
   Depression disorders                       
    Dysthymic disorder                        10 (1.0)
    Adjustment disorder with depression       4 (0.4)
    Bipolar depression                        1 (0.1)
    MDD                                       36 (3.7)
    Unspecified depression                    256 (26.3)
    Any depression                            285 (29.2)
  Neoplasms                                   158 (16.2)
  Anemia and other blood/antibody disorders   136 (13.9)
  Diabetes                                    269 (27.6)
  Circulatory system disorders                853 (87.5)
  Respiratory system disorders                414 (42.5)
  Eyes, nose, and throat                      262 (26.9)
  Digestive system disorders                  546 (56.0)
  Painful neuropathic disorders               281 (28.8)
  Musculoskeletal system disorders            679 (69.6)
  Symptoms, signs, ill-defined conditions     610 (62.6)
  Somatoform disorders                        130 (13.3)
  Neurasthenia                                39 (4.0)
  Substance use disorders                     30 (3.1)
  Sleep disorders                             241 (24.7)
  Number of comorbidities                     
   0                                          17 (1.7)
   1                                          44 (4.5)
   2                                          66 (6.8)
   ≥3                                         848 (87.0)

\*Unless otherwise indicated, all values represent number (%)

GAD: Generalized anxiety disorder; OCD: Obsessive-compulsive disorder; PTSD: Post-traumatic stress disorder; MDD: Major depressive disorder

A total of 607 study subjects (62.3%) had received one or more GAD-related medications (both those deemed potentially inappropriate and all others) from their GPs -- most commonly, benzodiazepines (43.7%), including both short-acting (24.8%) and long-acting (23.1%) formulations, and TCAs (25.6%) \[Table [3](#T3){ref-type="table"}\]. Nine percent of patients received SSRIs, and 0.9% received venlafaxine.

###### 

Numbers of study subjects receiving potentially inappropriate medications for treatment of GAD\*

  **Medication**                            **Potentially Inappropriate**   **Possibly Appropriate**   **Total**
  ----------------------------------------- ------------------------------- -------------------------- ------------
  Benzodiazepines                                                                                      
   Short-acting                                                                                        
    Alprazolam^1^                           0 (0.0)                         29 (3.0)                   29 (3.0)
    Lorazepam^2^                            50 (5.1)                        21 (2.2)                   71 (7.3)
    Lormetazepam                            14 (1.4)                        0 (0.0)                    14 (1.4)
    Oxazepam^3^                             0 (0.0)                         88 (9.0)                   88 (9.0)
    Temazepam^4^                            8 (0.8)                         0 (0.0)                    8 (0.8)
    Tetrazepam                              0 (0.0)                         29 (3.0)                   29 (3.0)
    Triazolam^5^                            0 (0.0)                         1 (0.1)                    1 (0.1)
    Zolpidem^6^                             32 (3.3)                        3 (0.3)                    34 (3.5)
    Any of above                            97 (9.9)                        162 (16.6)                 242 (24.8)
   Long-acting\*\*                                                                                     
    Chlordiazepoxide                        6 (0.6)                         \-\--                      6 (0.6)
    Chlorazepate                            11 (1.1)                        \-\--                      11 (1.1)
    Clobazam                                2 (0.2)                         \-\--                      2 (0.2)
    Clonazepam                              3 (0.3)                         \-\--                      3 (0.3)
    Diazepam                                91 (9.3)                        \-\--                      91 (9.3)
    Flunitrazepam                           7 (0.7)                         \-\--                      7 (0.7)
    Flurazepam                              6 (0.6)                         \-\--                      6 (0.6)
    Halazepam                               0 (0.0)                         \-\--                      0 (0.0)
    Medazepam                               5 (0.5)                         \-\--                      5 (0.5)
    Nordazepam                              2 (0.2)                         \-\--                      2 (0.2)
    Prezepam                                0 (0.0)                         \-\--                      0 (0.0)
    Bromazepam                              93 (9.5)                        \-\--                      93 (9.5)
    Nitrazepam                              14 (1.4)                        \-\--                      14 (1.4)
    Midazolam                               0 (0.0)                         \-\--                      0 (0.0)
    Any of above                            225 (23.1)                      \-\--                      225 (23.1)
   Any of above                             298 (30.6)                      162 (16.6)                 426 (43.7)
  Tricyclic antidepressants                                                                            
   Amitriptyline                            52 (5.3)                        \-\--                      52 (5.3)
   Amitriptylinoxide                        0 (0.0)                         3 (0.3)                    3 (0.3)
   Clomipramine                             0 (0.0)                         4 (0.4)                    4 (0.4)
   Dibenzepin                               0 (0.0)                         3 (0.3)                    3 (0.3)
   Desipramine                              0 (0.0)                         0 (0.0)                    0 (0.0)
   Doxepin                                  70 (7.2)                        \-\--                      70 (7.2)
   Imipramine                               0 (0.0)                         0 (0.0)                    0 (0.0)
   Maprotiline                              0 (0.0)                         4 (0.4)                    4 (0.4)
   Nortriptyline                            0 (0.0)                         0 (0.0)                    0 (0.0)
   Opipramol                                0 (0.0)                         105 (10.8)                 105 (10.8)
   Trimipramine                             0 (0.0)                         29 (3.0)                   29 (3.0)
   Any of above                             119 (12.2)                      142 (14.6)                 250 (25.6)
  Selective serotonin reuptake inhibitors                                                              
   Escitalopram                             0 (0.0)                         7 (0.7)                    7 (0.7)
   Citalopram                               0 (0.0)                         40 (4.1)                   40 (4.1)
   Fluoxetine                               11 (1.1)                        0 (0.0)                    11 (1.1)
   Fluvoxamine                              0 (0.0)                         3 (0.3)                    3 (0.3)
   Paroxetine                               0 (0.0)                         16 (1.6)                   16 (1.6)
   Sertraline                               0 (0.0)                         13 (1.3)                   13 (1.3)
   Any of above                             11 (1.1)                        77 (7.9)                   86 (8.8)
  Venlafaxine                               0 (0.0)                         9 (0.9)                    9 (0.9)
  Hydroxyzine                               4 (0.4)                         \-\--                      4 (0.4)
  Buspirone                                 0 (0.0)                         5 (0.5)                    5 (0.5)
  Pregabalin                                0 (0.0)                         0 (0.0)                    0 (0.0)
  Trifluoperazine                           0 (0.0)                         0 (0.0)                    0 (0.0)
  Any of above                              392 (40.2)                      345 (35.4)                 607 (62.3)

\*All values are number of patients (%); dose calculated using all values found in database

\*\*Any use of long-acting benzodiazepines deemed potentially inappropriate

^1^Dose \>2 mg/d deemed potentially inappropriate

^2^Dose \>3 mg/d deemed potentially inappropriate

^3^Dose \>60 mg/d deemed potentially inappropriate

^4^Dose \>15 mg/d deemed potentially inappropriate

^5^Dose \> 0.25 mg/d deemed potentially inappropriate

^6^Dose \>5 mg/d deemed potentially inappropriate

GAD: Generalized anxiety disorder

About forty percent of study subjects -- or two-thirds of patients (64.6%) with evidence of receipt of GAD-related medications -- were dispensed at least one therapy considered potentially inappropriate for use in the elderly. Ten percent of patients received short-acting benzodiazepines at dosages that rendered their use potentially inappropriate, 23.1% received long-acting benzodiazepines, and 12.2% received amitriptyline or doxepin (primarily doxepin).

Receipt of potentially inappropriate therapy did not differ by age (39.1% for patients aged 65--74 years vs 41.5% for patients aged ≥75 years; p = 0.45) or gender (41.1% of men vs 37.9% of women; p = 0.36). Patients with comorbid depression were more likely to receive potentially inappropriate therapy (51.6% vs 35.5% for those without comorbid depression; p \< 0.01), as were those with digestive system disorders (43.0% vs 36.6% for those without these disorders; p = 0.04), and those with sleep disorders (62.2% vs 33.0% for those without these disorders; p \< 0.01); receipt of these therapies did not differ significantly for patients with versus without any of the other selected comorbidities.

Discussion
==========

GAD can be difficult to treat, and several different medications -- including benzodiazepines, buspirone, TCAs, and SSRIs -- are recommended for use in these patients \[[@B5]-[@B7]\]. Although these therapies are often of benefit, they also can confer significant risks in older adults. Because of these risks, some of these drugs have been designated potentially inappropriate for use in persons aged 65 years or older.

Using the 1997 Beers criteria \[[@B11]\] and subsequent updates \[[@B13],[@B14]\], we found that four out of every 10 patients -- and two out of every three of those who received any GAD-related therapy -- received medications that have been designated as potentially inappropriate for use among persons aged 65 years and older. Notably, use of these medications did not differ between the \"young\" old versus the \"old\" old (i.e., aged 65--74 years vs ≥ 75 years).

Benzodiazepines have long been the mainstay of pharmacologic treatment for GAD, and they were the medication most commonly dispensed among subjects in our study: 44% of patients in our study received these agents. Paradoxically, they also comprise the majority of agents deemed potentially inappropriate for use in the elderly, due in part to an increased risk of falls, hip fractures, drug-induced disorders of cognition, and motor vehicle accidents \[[@B9],[@B24]-[@B27]\]. We note that GPs dispensed short-acting benzodiazepines at daily doses deemed potentially inappropriate to 10% of study subjects; they also dispensed long-acting benzodiazepines -- which are deemed potentially inappropriate in older patients regardless of daily dose -- to 31% of patients. About one in 10 patients in our study received TCAs deemed potentially inappropriate -- either amitriptyline or doxepin -- despite the fact that several other TCAs (e.g., nortriptyline) are available with similar efficacy that are better tolerated by older patients. We are unaware of any other study of potentially inappropriate prescribing in patients (of any age) with GAD. Compared with rates of potentially inappropriate prescribing reported among the elderly in general \[[@B13],[@B16]-[@B21],[@B28]\], the rates we report are considerably higher. This finding is consistent, however, with the fact that many of the medications that have been designated by some experts as potentially inappropriate in the elderly are also commonly recommended by other experts to treat GAD.

As people age, their ability to metabolize drugs decreases, and receptor sensitivity to the effects of pharmacotherapy changes \[[@B29],[@B30]\]. Unfortunately, older adults are often underrepresented in randomized controlled trials \[[@B15]\], an important source of information for prescribers. Consequently, physicians may sometimes prescribe therapies on presumptions of efficacy and safety based on clinical trial results that are not necessarily generalizable to persons of advanced age. This may explain why we found that so many patients with GAD received medications that were potentially inappropriate. Inappropriate prescribing also may result from the use of inappropriate doses of otherwise age-appropriate medications and/or not prescribing medications that may be of benefit (e.g., not prescribing GAD-related therapies for patients with this condition) \[[@B31]\]. Accordingly, our findings probably underestimate the magnitude of potentially inappropriate prescribing in Germany among older patients with GAD. Further study is needed to ascertain the extent to which these other aspects of potentially inappropriate prescribing are evident in this patient population.

The clinical implication of our findings appears to be that benzodiazepines, amitriptyline, and doxepin are being overprescribed in Germany among elderly patients with GAD, especially among those with comorbid depression and/or sleep disorders. A major limitation of our study, however, is that we cannot assess the actual extent to which prescribing was truly clinically inappropriate. The treatment of GAD in the elderly is clinically complex and presents many challenges. Since we did not employ a \"therapeutic timeline\" as part of our research design, patients could have received potentially inappropriate agents either as initial treatment or following failure of safer, more appropriate agents. To the extent that the latter occurred, providers may have known about the risks associated with these medications and nonetheless used them only after a careful balancing of these risks against their potential benefits in patients with severe symptoms \[[@B29]\]. Further study is needed to clarify the extent of truly clinically inappropriate prescribing.

A second limitation of our study is that the list of potentially inappropriate agents may be too rigid. For example, while Beers classified amitriptyline as potentially inappropriate, Zhan et al. \[[@B13]\] deemed the use of low doses of this agent as appropriate in older adults in some instances, such as for the treatment of neuropathic pain. We note, however, that the Beers criteria are not disease-specific; these agents are deemed potentially inappropriate based exclusively on age ≥65 years. Furthermore, the panel convened by Zhan et al. concluded that drugs such as amitriptyline \"are often misused in clinical practice\" \[[@B13]\].

Finally, we note that the database was limited to information from encounters with GPs. Patients who were seen for the treatment of GAD by psychiatrists may not have been included in our study (unless they also received a diagnosis of GAD from their GPs). Moreover, all information on prescription drugs is limited to those that are dispensed by GPs. The generalizability of our findings to all older patients with GAD is therefore unknown.

Conclusion
==========

GPs in Germany often prescribe medications that have been designated as potentially inappropriate to their elderly patients with GAD -- especially those with comorbid depressive disorders. Further research is needed to ascertain whether there are specific subgoups of elderly patients with GAD for whom the benefits of these medications outweigh their risks.
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